Immuneering Corporation
Latest round
- Series B
Last raised
- Dec 2020
Total raised
- $57M
Investors
- 8
About Immuneering Corporation
Based in Massachusetts, US, and founded in 2008, Immuneering Corporation operates as a bioinformatics company that develops and researches treatments for cancer cachexia and metastasis. The company has 32 employees as of July 2021 and was co-founded by Ben Zeskind (CEO) and Bob Carpenter.5 million shares at USD 15 per share on the Nasdaq. Immuneering Corporation develops proprietary Disease Cancelling Technology (DCT) where they use a method for reversing a disease signal across many relevant genes. The company also provides Dual MEK, Covalent MEK, and KRAS4B that focus on the discovery stage of drug development. Immuneering Corporation plans to develop its Disease Cancelling Technology (DCT) platform, enhance its computational biology services business, and submit an IND for IMM-1-104 in the first quarter of 2022.
Who invested in Immuneering Corporation
8 investors across 2 rounds
See all investors in Immuneering Corporation
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Immuneering Corporation
Who invested in Immuneering Corporation?
Immuneering Corporation has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Immuneering Corporation raised?
Immuneering Corporation has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Immuneering Corporation last raise money?
Immuneering Corporation's most recent round on record is a Series B, in Dec 2020.
What does Immuneering Corporation do?
Based in Massachusetts, US, and founded in 2008, Immuneering Corporation operates as a bioinformatics company that develops and researches treatments for cancer cachexia and metastasis.
Where is Immuneering Corporation headquartered?
Immuneering Corporation is headquartered in Cambridge, US.
Which VCs invest in companies like Immuneering Corporation?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Immuneering Corporation's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Immuneering Corporation? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.